Cell Death Identification in Anticancer Therapy-Letter.
Cell Death Identification in Anticancer Therapy-Letter.
复制标题
抗癌治疗中的细胞死亡识别-信函。
DOI：
10.1158/0008-5472.can-15-0908
复制
发表时间：
2015
期刊：
影响因子：
11.2
通讯作者：
Kirsch,DavidG
中科院分区：
文献类型：
--
作者：
Brown,JMartin;Wouters,BradlyG;Kirsch,DavidG
在他们最近的评论中，Rello-Varona 及其同事 (1) 强调“在与癌症研究相关的每个实验环境中，必须正确评估细胞死亡。”因此，他们讨论了识别死亡细胞并区分各种形式的细胞死亡的各种方法。虽然我们同意他们对不同形式的细胞死亡的描述，并认识到细胞死亡的机制在癌症研究中通常值得表征，但我们要强调细胞杀伤的三个方面，这使得在评估癌症治疗时使用克隆形成终点对细胞存活进行量化相比，细胞死亡类型的精确表征并不那么重要：（1）大多数癌症治疗（通常是 DNA 损伤剂）导致的细胞死亡模式，尽管通常不是最终的杀伤（或存活）水平，但高度依赖于细胞死亡的模式。肿瘤细胞的遗传学。例如，体外细胞、实体瘤或某些正常组织中发生的细胞凋亡的量可显着受到Bcl-2 (2) Bax或Bak1 (3)、p53或p21 (4)状态的影响，
In their recent review, Rello-Varona and colleagues (1) emphasize that" The correct evaluation of cell death in every experimental setting related to cancer research is a must." Accordingly, they discuss the variety of methods to identify dead cells and to distinguish the various forms of cell death from one another. While we agree with their descriptions of the different forms of cell death and appreciate that the mechanism of cell death is often worth characterizing in cancer research, we would emphasize three aspects of cell killing that make the precise characterization of the type of cell death less important than the quantification of cell survival using clonogenic endpoints when evaluating cancer therapies:(1) The mode of cell death, though often not the eventual level of killing (or survival), resulting from the majority of cancer therapies (typically DNA-damaging agents), is highly dependent on the genetics of the tumor cell. For example, the amount of apoptosis occurring in cells in vitro, in solid tumors, or in certain normal tissues can be markedly affected by Bcl-2 (2) Bax or Bak1 (3), p53 or p21 (4) status,